Oliver Kiss
Overview
Explore the profile of Oliver Kiss including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
4
Citations
20
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Zippel C, Ermert J, Patt M, Gildehaus F, Ross T, Reischl G, et al.
Front Nucl Med
. 2024 Oct;
2:850414.
PMID: 39354976
Background: Cyclotrons form a central infrastructure and are a resource of medical radionuclides for the development of new radiotracers as well as the production and supply of clinically established radiopharmaceuticals...
2.
Korde A, Patt M, Selivanova S, Scott A, Hesselmann R, Kiss O, et al.
EJNMMI Radiopharm Chem
. 2024 Jan;
9(1):2.
PMID: 38165504
Background: Nuclear medicine has made enormous progress in the past decades. However, there are still significant inequalities in patient access among different countries, which could be mitigated by improving access...
3.
Kniess T, Zessin J, Mading P, Kuchar M, Kiss O, Kopka K
EJNMMI Radiopharm Chem
. 2023 Mar;
8(1):5.
PMID: 36897480
Background: [F]fluoromisonidazole ([F]FMISO, 1H-1-(3-[F]fluoro-2-hydroxypropyl)-2-nitroimidazole) is a commonly used radiotracer for imaging hypoxic conditions in cells. Since hypoxia is prevalent in solid tumors, [F]FMISO is in clinical application for decades to...
4.
Hendrikse H, Kiss O, Kunikowska J, Wadsak W, Decristoforo C, Patt M
Eur J Nucl Med Mol Imaging
. 2022 Jan;
49(4):1095-1098.
PMID: 35050391
The EANM herewith clearly expresses its commitment and support to the non-commercial in-house preparation of radiopharmaceuticals for direct use in accordance with European and national regulations.